TopRight Nordic AB (publ) (NGM:TOPR) made a public offer to acquire ChromoGenics AB (OM:CHRO) on March 3, 2021. Pursuant to the terms of the offer, TopRight Nordic AB (publ) will be acquiring all the shares and TO3 series warrants in ChromoGenics AB. TopRight Nordic AB (publ) will be offering its own newly issued shares.

The offer does not include any cash compensation. ChromoGenics AB will become part of TopRight Nordic AB (publ)'s supply chain. The acquisition will have a negative impact on employment at ChromoGenics AB's office in Uppsala and that the management functions for ChromoGenics AB's operations will be based in Gothenburg instead of Uppsala.

The two companies' head offices will be co-located in Gothenburg. The offer is conditional upon it being accepted to such extent that TopRight Nordic AB (publ) becomes the owner of the shares more than 60% of the total number of the shares in ChromoGenics AB after full dilution. TopRight Nordic AB (publ) reserves the right to waive all or part of the terms of the offer and to complete the offer at a lower connection rate than 60%.

The offer requires the approval by the next Annual General Meeting with the shareholders of TopRight Nordic AB (publ). As of March 10, 2021, the Board of TopRight Nordic AB (publ) has unanimously decided to advise the shareholders of ChromoGenics AB against accepting the offer.